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Short title: Foscan and Foslip based photodynamic therapy in osteosarcoma. 
Novelty and impact: Osteosarcoma is a devastating disease associated with impaired survival 
rates and treatment induced side effects, due to high tumor heterogeneity, chemoresistance and 
drug toxicity. We suggest photodynamic therapy using Foscan and its liposomal formulation 
Foslip as a novel approach for the treatment of metastasizing osteosarcoma. The present study 
demonstrates the inhibition of tumor growth and immune system-dependent suppression of 
metastatic spread by PDT with Foscan and Foslip in two different clinical relevant 
osteosarcoma mouse models. 
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Abstract 
Current osteosarcoma therapies cause severe treatment-related side effects and 
chemoresistance, and have low success rates. Consequently, alternative treatment options are 
urgently needed. Photodynamic therapy (PDT) is a minimally invasive, local therapy with 
proven clinical efficacy for a variety of tumor types. PDT is cytotoxic, provokes anti-vascular 
effects and stimulates tumor cell targeting mechanisms of the immune system and, 
consequently, has potential as a novel therapy for osteosarcoma patients. This study 
investigated the uptake and the dark- and phototoxicity and cytotoxic mechanisms of the 
photosensitizer (PS) 5,10,15,20-tetrakis(meta-hydroxyphenyl) chlorine (mTHPC, Foscan) and 
a liposomal mTHPC formulation (Foslip) in the human 143B and a mouse K7M2-derived 
osteosaroma cell line (K7M2L2) in vitro. Secondly the tumor- and metastasis-suppressive 
efficacies of mTHPC formulations based PDT and associated mechanisms in intratibial, 
metastasizing osteosarcoma mouse models (143B/SCID and syngeneic K7M2L2/BALB/c) 
were studied. The uptake of Foscan and Foslip in vitro was time- and dose-dependent and 
resulted in mTHPC and light dose-dependent phototoxicity associated with apoptosis. In vivo, 
the uptake of both i.v. administered mTHPC formulations was higher in tumor than in healthy 
control tissue. PDT caused significant (Foscan P<0.05, Foslip P<0.001) tumor growth 
inhibition in both models. A significant (Foscan P<0.001, Foslip P<0.001) immunsystem-
dependent suppression of lung metastasis was only observed in the K7M2L2/BALB/c model 
and was associated with a marked infiltration of T-lymphocytes at the primary tumor site.  
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In conclusion, mTHPC-based PDT is effective in clinically relevant experimental 
osteosarcoma and suppresses lung metastasis in immunocompetent mice with beneficial effects 
of the liposomal mTHPC formulation Foslip. 
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Introduction 
Osteosarcoma is the most common primary high-grade bone neoplasm and one of the deadliest 
cancer types in children and adolescents
1, 2
. Since the introduction of new treatment protocols 
in the 70ies, including neoadjuvant and adjuvant chemotherapy, the 5-year survival rate (5-ysr) 
of patients with localized disease increased significantly to approximately 60% but plateaued 
ever since
3, 4
. However, patients with metastatic disease, with lesions most frequently 
developing in the lungs and other bones, continue to have a poor 5-ysr of approximately 30%
5
. 
Unfortunately, multi-drug therapy, using high-dose methotrexate, cisplatin, and doxorubicin, is 
associated with a variety of severe side effects ranging from gastrointestinal problems, 
neutropenia, cardiac toxicity, neurological dysfunction, second malignant neoplasms to even 
death
6, 7
. Although multi-agent chemotherapy increased the survival of patients, it plateaued 
over the last three decades, most probably owing to the high tumor heterogeneity of 
osteosarcoma and to chemoresistance
8, 9
. The lack of novel, more effective therapeutic 
strategies for metastasizing osteosarcoma has become an increasing problem. 
During the last four decades, photodynamic therapy (PDT) evolved into a novel 
attractive treatment option for a variety of cancer types
10
. PDT is a multi-step process making 
use of three components; photosensitizer (PS), light and oxygen
11
. In a first step of the therapy, 
PS is injected into the blood stream and is taken up by tumor and also by healthy cells. Next, 
tumor-selective PDT is achieved by local illumination of the tumor site with light, which 
activates the light-sensitive PS to a higher energy state and results in the direct or indirect 
transfer of excess energy to neighboring oxygen molecules or tissue molecules, producing cell-
toxic reactive oxygen. Finally, in addition to eliciting direct cytotoxicity, PDT provokes a 
variety of additional beneficial anti-tumor effects such as an acute inflammatory response, anti-
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vascular effects and an activation of the immune system
11
. PDT has commonly been employed 
for the treatment of solid tumors at superficial anatomical locations, however, its application in 
other tumors at more inaccessible sites has become an aim of clinical investigations
12, 13
. 
Additionally to the advantage of PDT as a local application, also a systemic immune response 
against tumors have been reported
14-16
, therefore PDT is potentially not only effective against 
local tumor growth but also against distant metastases.  
PDT is associated with good functional and aesthetic outcomes and clinical studies 
reported it as a good treatment option for patients unsuitable for other treatments in head and 
neck cancers
17, 18
, but studies investigating potential therapeutic applications in osteosarcoma 
are scarce. In vitro investigations demonstrated strong cytotoxic effects of PDT in different 
osteosarcoma cells lines
19-22
. Preclinical studies in osteosarcoma mouse models showed an 
inhibition of local tumor growth
23, 24
, but these studies were either performed in subcutaneous 
osteosarcoma mouse models, which do not reproduce the clinical situation, or in immune 
suppressed mice, where the impact on distant metastases cannot be evaluated. Nevertheless, a 
preclinical study by Burch et al., who applied PDT in dogs that spontaneously developed 
osteosarcoma, demonstrated substantial tumor necrosis, indicating the potential of PDT for 
effective treatment of osteosarcoma, but long-term effects or treatment impact on metastases 
were not reported
25
. 
One of the most powerful and commonly used PS is 5,10,15,20-tetrakis(meta-
hydroxyphenyl)chlorine (mTHPC), traded under the name Foscan®. Although mTHPC is a 
potent PS, its high hydrophobicity restricts the routes of administration. Encapsulation of 
mTHPC into liposomal structures, however, achieved with the formulation Foslip used in the 
present study, makes it water soluble, which potentially increases PDT efficacy
26-28
.  
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In this study, we investigated the uptake and the dark- and phototoxicity of Foscan and 
Foslip in the human 143B and in a derivative (K7M2L2) of the mouse K7M2 osteosarcoma 
cell line. In addition, we studied the efficacies of Foscan- and Foslip-based PDT in a 143B cell 
line-dependent intratibial xenograft osteosarcoma model in SCID mice and in an intratibial 
K7M2L2 cell line-derived model in syngeneic, immune competent BALB/c mice. Tumors in 
both models metastasize to the lung. Thus, these models allowed us to compare the tumor- and 
metastasis-suppressive potential of Foscan- and Foslip-based PDT in the absence and in the 
presence of a functional immune system. The results demonstrated promising tumor and 
immune system-dependent metastasis suppressive effects and anti-vascular activity of the here 
applied PDT in a clinically relevant experimental osteosarcoma model. 
Materials and Methods 
Photosensitizer and OS cell lines 
Foscan and Foslip were kindly provided by Biolitec research GmbH (Jena, Germany). Foscan was 
reconstituted and diluted in ethanol (40% w/w) and propylene glycol (60% w/w). Foslip, a 
liposomal formulation of mTHPC, is a 9:1 mixture of dipalmitoylphosphatidylcholine (DPPC) and 
dipalmitoylphosphatidylglycerol (DPPG; >99% purity). Foslip (freeze-dried product) was 
reconstituted with water to 1.5 mg mTHPC/ml and further diluted in 5% glucose. 
Human 143B osteosarcoma cells were purchased from ECACC (Salisbury, UK) and 
murine K7M2 osteosarcoma cells (CRL-2836) were kindly provided by Dr. Chand Khanna 
(Center for Cancer Research National Institute, Bethesda, USA). Cells were cultured in DMEM 
(4.5 g/l glucose)/HamF12 (1:1) medium (Invitrogen, Carlsbad, CA), supplemented with 10% heat-
inactivated FCS (GIBCO, Basel, Switzerland), at 37°C in a humidified atmosphere of 5% CO2 air. 
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Both cell lines were transduced with a lacZ reporter gene
29
. 3 x 10
5
 of K7M2/lacZ cells 
were intratibially (i.t.) injected into female, 8 week old BALB/c mice as described
30
. The 
K7M2L2/lacZ cell line was obtained after two rounds of in vivo selection of metastatic lacZ 
expressing cells within the lung according to Fidler’s method
31
.  
Uptake of mTHPC in vitro 
143B/lacZ and K7M2L2/lacZ (referred to as 143B and K7M2L2) cells were seeded in six well 
plates (2000 cells/well for dose dependent uptake and 800 cells/well for time-dependent uptake) 
and allowed to adhere overnight. In time-course experiments, cells were incubated under tissue 
culture conditions with Foscan or Foslip equivalent to 2.5 µg/ml mTHPC for 0 - 48 h. For dose-
dependent uptake, the cells were incubated for 5 h in the dark in tissue culture medium containing 
PS formulations equivalent to 0 - 10µg/ml mTHPC. Subsequently, the cells were washed two 
times with 100 µl PBS before the fluorescence of the cells in 100 µl PBS was measured at 652 nm 
with excitation at 417 nm in a Spectramax Gemini XS plate reader (Molecular Devices, 
Sunnyvale, CA). Results were obtained as relative fluorescence unit (RFU). 
Subcellular localization of mTHPC (Foscan and Foslip) was visualized by confocal laser 
scanning microscopy as previously described
19
. Cells were stained with Hoechst (Life 
Technologies, Carlsbad, USA). 
Cytotoxicity assay 
143B and K7M2L2 cells (2500 cells / well) were incubated under tissue culture conditions for 5 h 
at different concentrations of Foslip or Foscan (0 - 200 µg/ml mTHPC) and left untreated in the 
dark or illuminated with 652 nm laser light at an energy dose of 1 J/cm
2
 or 5 J/cm
2
 (21.88 
mW/cm
2
) as described previously
19
. 24 hours later, the cell viability was measured with the water-
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soluble tetrazolium (WST-1) assay (Roche, Basel, Switzerland) according to the manufacturer’s 
protocol. 
Western Blot analysis of apoptosis 
10
6
 143B or K7M2L2 cells were seeded in 6 cm cell culture dishes. After overnight adherence, 
cells were incubated under tissue culture conditions for 5 h with Foscan or Foslip (0.6 µg/ml 
mTHPC) and pre-incubated for 1 h with or without the pan-caspase inhibitor Z-VAD-FMK (100 
µM) or its solvent control (1% DMSO) (BD Pharmingen AG, Allschwil, Switzerland). Cells were 
illuminated and protein extracts were analyzed for PARP and cleaved PARP (1:1000, Cell 
Signaling Technology) and GAPDH (protein loading control) (1:3000, Santa Cruz 
Biotechnologies, Texas, USA) as previously described
19
.  
Intratibial human xenograft and syngeneic osteosarcoma mouse models 
All studies were conducted with the approval of the Veterinary Office Kanton Zurich, 
Switzerland (animal application license 167/2012) and in accordance with the guidelines of the 
Swiss Federal Veterinary Office. Eight-week-old female SCID and BALB/c mice were 
obtained from Charles River Laboratories. 10
5
 143B/lacZ cells in 10 µl PBS/0.05% EDTA 
were injected i.t. into SCID mice (143B/SCID) (human xenograft mouse model) and 10
5
 
K7M2L2/lacZ cells in 10 µl PBS/0.05% EDTA i.t. into BALB/c mice (K7M2L2/BALB/c) 
(syngeneic mouse model) as previously described
30
.  
In vivo uptake of Foscan and Foslip by intratibial tumors 
Upon formation of a tumor (>50 mm
3
), Foscan or Foslip at doses equivalent to 1.5 mg/kg mTHPC 
were administered to the mice (143B/SCID n=10, K7M2L2/BALB/c n=14) with a slow (4-6 min) 
intravenous (i.v.) injection in the tail vein. The mice were then kept in a darkened environment for 
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the rest of the experiment. The area of the leg where the tumor was localized was shaved and the 
mTHPC uptake by the tumor was measured with a PDT fluorometer (JETI Technische Instrumente 
GmbH, Jena, Germany) in three different locations on the surface of the skin covering the tumor 
(excitation 405 nm, emission 550-800 nm). Background fluorescence of intratibial tumor tissue 
was measured (integration time 7500 ms) in a mouse without PS injection and was subtracted from 
each measurement resulting in RFU. The mean RFU of the tumor in individual PS-injected mice 
was calculated from all three emission peak values detected at 652 nm. Upon sacrifice, tumors 
were cut longitudinally into halves and mTHPC fluorescence was measured inside the tumor tissue 
in three different locations as described above. 
PDT protocol 
In both, the xenograft and the syngeneic osteosarcoma model, the mice were randomly assigned to 
three groups; a control group receiving PS but no illumination (143B/SCID n=10, 
K7M2L2/BALB/c n=15), a group receiving Foscan-based PDT (143B/SCID n=7, 
K7M2L2/BALB/c n=8) and a group that was subjected to Foslip-based PDT (143B/SCID n=7, 
K7M2L2/BALB/c n=9). Foscan or Foslip control mice revealed no difference in any experimental 
analyses and were therefore merged and presented as one control group (data not shown). A 
control group of mice that were only illuminated without PS injection was not included here since 
preliminary studies showed no effect of illumination alone on tumor development (data not 
shown). Treatment was started after the formation of a tumor (>50 mm
3
). Both legs were shaved 
and the mice were injected with Temgesic (i.p., 0.1 mg/kg). Foscan or Foslip (mTHPC 0.15 
mg/kg) were administered by i.v. injection (4-6 min). The mice were kept in a darkened 
environment for the rest of the experiment. 24 h after mTHPC injection, the mice were 
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anaesthetized (1-5% isoflurane/O2) and covered with aluminum foil and black paper such that only 
the primary tumor within the left hind leg was exposed. The tumors in the PDT groups were 
illuminated at an energy dose of 20 J/cm
2
 (26.817 mW/cm
2
, 720 sec) with a 652 nm diode laser 
(Applied Optronics Corp., South Plainfield, NJ), equipped with a fiber-based frontal light 
distributor (Medlight SA, Ecublens, Switzerland). Primary tumor growth over time after PDT was 
monitored by caliper ruler measurements at indicated time points and the data are presented as 
tumor volume fold-change, comparing the tumor volume in individual mice with the respective 
volume on the day of PDT. 
In the xenograft model (143B/SCID), the mice were sacrificed 14 days after PDT. In the 
syngeneic model (K7M2L2/BALB/c), three mice per group were sacrificed 2 days after 
illumination for histological analyses of tumor tissue; all other mice were sacrificed 10 days after 
PDT.  
Pulmonary metastases 
After sacrifice of the mice in situ, lung perfusion was performed. The lungs were dissected and 
stained with X-gal for lacZ-transduced tumor cells as previously described
32
. 
Histological analyses in tumor-bearing BALB/c mice 
mTHPC fluorescence in primary tumor tissue: Pieces of primary tumor tissue were embedded in 
mounting medium (Dako, Denmark) and snap frozen in liquid nitrogen. mTHPC in 10 µm sections 
of primary tumor tissue was visualized with an AxioCam MRm camera connected to a Zeiss 
Observer.Z1 inverted microscope (Carl Zeiss MicroImaging GmbH) set to 4x magnification and 
equipped with a fluorescent filter for excitation at 488 nm and detection of emission at 600-700 
nm. 
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Histological stainings: Tumor tissue dissected from the hind-limb at sacrifice was fixed in 4% 
paraformaldehyde and subsequently decalcified in Osteosoft (Merck Millipore, Germany). The 
tumors were trimmed, dehydrated in graded alcohol and embedded in paraffin according to 
standard protocols. Sections of 5-10 µm were mounted on glass slides, deparaffinized in xylene, 
rehydrated in graded alcohol and stained with hematoxylin and eosin (HE). 
Tumor necrosis was assessed in the HE-stained sections as follows: Grade 0: no necrosis; 
Grade 1: necrosis below 20%; Grade 2: necrosis > 20% and < 40%; Grade 3: necrosis > 40% and 
< 60%; Grade 4: necrosis > 60% and <80%; Grade 5: necrosis > 80%. Apoptosis was assessed by 
immunostaining with an antibody to cleaved caspase 3 (Cell Signaling) and tumor vascularization 
by staining with an antibody to CD31 (Santa Cruz Biotechnologies), a cell surface marker of 
endothelial cells
33
. The number of apoptotic cells present in tumor sections was normalized to the 
total number of cells (apoptotic index
34
). Visiomorph software (Visiopharm, Denmark) was 
employed to calculate the apoptotic index was determined by counting at least 2500 cells in 
randomly selected areas of tumor tissue sections free of necrosis. Numbers of T (CD3 
immunostaining, Spring Biosciences) and B (CD45R immunostaining, BD Biosciences) 
lymphocytes were counted with the same software in 20 high power fields (HPF) randomly 
selected in the core and at the periphery of the tumors, avoiding areas of frank necrosis, and in the 
lungs. Data are presented as the mean (± SEM) number of stained cells/HPF. 
Assessment of hind limb blood vessel perfusion 
Mice were anesthetized (1-5% isoflurane) and placed in supine position under the laser Doppler 
perfusion imager (Moor instruments Ltd., UK). Tissue perfusion was measured before PDT and 2, 
7 and 10 days after illumination at a speed of 4 ms/pixel using moorLDI Measurement v6.0 
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software (Moor instruments Ltd., UK). The results were analyzed by drawing a region of interest 
(ROI) around areas of tumor growth and the corresponding contralateral region in the control limb 
(normal tissue) using moorLDI Review v6.0. The branching of the epigastric vein from the 
femoral vein and the branching of the caudal femoral vein were used as anatomical landmarks to 
define the ROI. The percent difference in perfusion of tumor compared to normal tissue was 
calculated using the following formula: (1- (fluxnormal / fluxtumor)) x 100. 
Statistical analysis 
In vitro experiments show results of three independent experiments. The results are presented as 
the mean ± standard error of the mean (SEM) if not described otherwise. Statistical significance of 
differences between groups was determined using one-way ANOVA with Bonferroni post hoc test. 
Two-way repeated measures ANOVA with Bonferroni’s post-test analysis was used to compare 
mTHPC uptake in vitro and in vivo and treatment efficacy (tumor volume, blood vessel perfusion). 
Statistical analyses were performed using GraphPad Prism Version 5.01 software (GraphPad 
Software, Inc.). A P value below 0.05 was considered to be statistically significant. 
Results  
Cellular uptake of Foscan and Foslip in osteosarcoma cell lines 
In both human 143B and murine K7M2L2 osteosarcoma cells, Foscan and Foslip were taken 
up in a dose- and time-dependent manner (Figs. 1a, b). No differences in cellular uptake of 
Foscan and Foslip were observed at mTHPC concentrations up to 10 µg/ml (Fig. 1a). In time 
course experiments, both the 143B and K7M2L2 cell lines exhibited a slightly delayed uptake 
of Foslip compared to Foscan, but the difference was no longer significant after 48 h of 
incubation (Fig. 1b). Confocal laser scanning microscopy of 143B and K7M2L2 cells 
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incubated with Foscan and Foslip showed a cytoplasmic localization of mTHPC, but no 
mTHPC in the nucleus (Fig. 1c).  
 
Cytotoxicity of Foscan and Foslip  
To investigate differences in photo- and dark-toxicity of Foscan and Foslip in 143B and 
K7M2L2 osteosarcoma cells, the cells were incubated with the mTHPC formulations at 
indicated mTHPC concentrations. Foscan exhibited a dose-dependent dark-toxicity in 143B 
and K7M2L2 cells with half-maximal inhibitory doses (IC50) equivalent to 11.74 µg/ml and 
10.4 µg/ml mTHPC, respectively (Fig. 2a). In contrast, Foslip showed no detectable dark-
toxicity in both cell lines. Both, Foscan and Foslip showed mTHPC and a laser light dose-
dependent phototoxicity (Fig 2b). IC50 of Foscan and Foslip in 143B and K7M2L2 cells 
illuminated with 1 J/cm
2
 or 5 J/cm
2
 laser light are summarized in Supporting Information 
Table 1. The data show that the sensitivity of 143B and K7M2L2 cells to Foscan- and Foslip-
based PDT was laser light energy dose-dependent and overall comparable. 
Both Foscan and Foslip-based treatment induced apoptotic cell death, shown by the 
presence of cleaved PARP in extracts of cells subjected to PDT in both 143B (Fig. 2c) and 
K7M2L2 cells (Fig. 2d). In both cell lines, PARP cleavage was suppressed by pretreatment of 
the cells with the pan-caspase inhibitor Z-VAD-FMK prior to PDT, indicating a caspase 
dependent apoptosis pathway, confirmed by the detection of cleaved of caspase 3, 7 and 9 in 
the cell extracts (Supporting Information Figures 1a, b). 
 
In vivo uptake of Foslip and Foscan by primary tumors in the xenograft and syngeneic 
osteosarcoma mouse models 
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In order to compare the uptake of the mTHPC formulations Foscan and Foslip by intratibial 
primary tumors in the xenograft 143B/SCID and the syngeneic K7M2L2/BALB/c 
osteosarcoma mouse models, the PS formulations were i.v. injected into respective tumor-
bearing mice. The uptake by tumor tissue was monitored in vivo during 48 h and subsequently 
analyzed ex vivo. In both models, the two mTHPC formulations were taken up by the tumor 
tissue in a time dependent manner (Figs. 3a, b). In 143B cell line derived tumors, Foslip was 
taken up significantly more efficiently than Foscan (Fig. 3a), whereas in the K7M2L2 cell line 
derived tumors, the uptake of Foslip compared to Foscan was only significantly higher at 6 h 
after PS administration (Fig. 3b). Ex vivo measurements of mTHPC fluorescence in dissected 
tumor and healthy control leg tissue revealed a significant 2.4- and 2.7-times higher uptake of 
Foscan and Foslip, respectively, in 143B cell line-derived tumors than in the control tissue 
(Fig. 3c). Similarly, in the K7M2L2/BALB/c model, the uptake of Foscan and Foslip by tumor 
tissue was 3.4-and 4-times higher, respectively, than by control tissue (Fig. 3d). Based on these 
ex vivo measurements, the uptake of the two mTHPC formulations by tumor tissue was 
indistinguishable in both osteosarcoma mouse models.  
Fluorescence microscopy of tumor tissue cryosections showed a rather uniform 
distribution of mTHPC fluorescence of Foscan and Foslip in both osteosarcoma mouse 
models. The fluorescence in adjacent muscle tissue was considerably lower than in tumor 
tissue in both tumor models indicating again more efficient uptake of both mTHPC 
formulations by tumor than by healthy tissue (Fig. 3e).  
 
Anti-tumor efficacy of Foscan or Foslip–based PDT in the xenograft and syngeneic 
osteosarcoma mouse models 
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We next assessed the tumor suppressive potential of Foscan- and Foslip-based PDT in the two 
osteosarcoma mouse models. The growth of i.t. tumors derived from 143B cells in SCID mice, 
lacking functional T and B lymphocytes, was significantly inhibited by Foscan and Foslip-
based PDT and Foslip was slightly more effective than Foscan (Figs. 4a, c). Treatment-induced 
swelling of the tumor leg 3 days after PDT explained the observed transient increase in tumor 
volume. One week after PDT, the tumor volume of Foslip-treated mice was only 1.2-times and 
that of Foscan-treated animals only 1.8-times larger compared to the non-treated control mice, 
which had a 2.2-times larger tumors compared to before PDT. Two weeks after PDT, the 
tumor volume of the control mice was 4-times larger than before treatment start, whereas mice 
subjected to Foscan and Foslip-based treatment had only a 2.6-time and 1.8-times, 
respectively, larger tumors compared to before PDT. The difference in tumor volume in both 
groups of PDT treated mice was not statistically significant. 
In BALB/c mice with an intact immune system, the inhibition of tumor growth by 
Foscan- and Foslip-mediated PDT was even more pronounced than in SCID mice (Figs. 4b, d). 
One week after PDT, the tumors in Foscan- or Foslip-based PDT treated mice was 
indistinguishable and  only 2.4 times larger than before treatment compared to the non-treated 
control mice, which had a 7.8 times larger tumors compared to before PDT. At sacrifice of the 
mice, K7M2L2 cell line-derived tumors in non-treated mice were 14.3-times larger than at the 
beginning of the experiment. The tumors of Foscan/PDT treated animals were still only 2.7 
times larger and those of Foslip/PDT treated mice only 4.7 times larger than before treatment. 
In contrast, two days after laser light illumination of the tumor, a swelling and edema 
formation in the leg where the tumor was localized was observed in all mice subjected to 
PDT.In the PDT study performed in the KM2L2/BALB/c osteosarcoma model, three mice per 
Page 16 of 37
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
  
17
group were sacrificed 48 h after PDT to assess the extent of necrosis and apoptosis in the 
tumor tissue of treated and non-treated animals (Fig. 4e). Overall, the level of necrosis and 
apoptosis was remarkably higher in the PDT-treated than in control tumors, which only 
showed negligible areas of necrosis and cleaved-caspase 3 staining (average necrosis 
histological score: 0.3; average apoptotic index: 0.02%). Despite variability among the PDT-
treated tumors, Foscan/PDT treated tumors exhibited on average higher necrosis (average 
necrosis histological score: 4.5) and apoptosis (average apoptotic index: 7.5%) scores than 
those subjected to Foslip- based PDT (average necrosis histological score: 2.7; average 
apoptotic index: 2.6%). 
 
The effect of Foscan and Foslip - based PDT on pulmonary metastases 
To study the impact of the immune system on a putative systemic anti-tumor effect of PDT in 
experimental osteosarcoma, lungs were dissected at sacrifice from 143B/SCID and from 
K7M2L2/BALB/c mice 14 and 10 days after Foscan- or Foslip- based PDT. The number of 
micro- and macrometastases was assessed on the surface of lung whole mounts (Fig. 5 a - c). 
PDT with either Foscan or Foslip had no effect on pulmonary metastasis in SCID mice (Figs. 
5a, c). In contrast, in immunocompetent BALB/c mice, Foscan- and Foslip-based PDT 
significantly inhibited the formation of lung micro- and macro-metastases to a comparable 
extent (Figs. 5b, c). Thus, in experimental osteosarcoma investigated here, PDT requires an 
intact immune system to provoke a systemic anti-tumor effect. In agreement with this, we 
observed significantly higher numbers of T lymphocytes at the periphery of the tumors in 
BALB/c mice euthanized 10 days after PDT than in controls (Figure 5 d, f). The number of T 
lymphocytes in the core of the tumors was only significantly higher in the Foslip treated mice 
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(Figure e, f). The number of B lymphocytes in the tumors was comparable among the groups 
(data not shown). Likewise, the numbers of B- or T-lymphocytes within the lungs were not 
significantly different in the PDT treated and control groups (data not shown). 
 
PDT inhibits tumor perfusion in the syngeneic K7M2L2/BALB/c osteosarcoma mouse 
model 
Blood perfusion of the tumor-bearing and the healthy control hind-limb was measured prior to 
and after Foscan- and Foslip-based PDT. The perfusion of the tumor-bearing hind limb area 
before PDT was on average 45.5% higher than in the corresponding hind limb area of the 
control leg in all experimental groups of mice (Fig. 6a). Two days after PDT, a striking 
reduction of tumor perfusion was observed in the Foscan- and Foslip-based PDT treated mice 
(P < 0.001). Remarkably, on experimental day 7, the perfusion in the tumors in both treatment 
groups recovered to levels prior to PDT (Figs. 6.a, b).  
The effects of PDT on tumor vascularization were also investigated by histology and 
immunohistochemistry (Fig. 6c). CD31-immunostained endothelial cells were virtually absent 
in predominantly necrotic PDT-treated tumor areas, indicating disruption of vessels. In non-
necrotic areas of PDT-treated tumors CD31 immunostaining remained detectable, but at 
overall less density than that observed in tumor tissue not subjected to PDT, which showed 
moderate to high numbers of CD31-stained blood vessels.  
 
Discussion 
This study investigated the potential use of PDT in two clinically relevant models of experimental 
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osteosarcoma as a novel approach for effective treatment of metastasizing osteosarcoma. The 
study compared the uptake and dark- and phototoxicity in vitro and the efficacy of PDT in vivo 
with mTHPC in the free formulation Foscan and the liposomal formulation Foslip. It took 
advantage of the orthotopic human 143B and the mouse K7M2L2 cell line, which form primary 
intratibial tumors and lung metastases within two weeks after inoculation in immune-defective 
SCID and in syngeneic immune-competent BALB/c mice, respectively. 
The results of the experiments carried out in vitro, demonstrating comparable time- and 
dose-dependent uptake of both Foscan and Foslip in the two osteosarcoma cell lines, are in line 
with the results of previous studies performed in human biliary cancer cell lines
35
. Despite a 
slightly less efficient uptake of Foslip compared to Foscan by the two osteosarcoma cell lines over 
time, both compounds showed a comparable phototoxicity triggering apoptosis, but importantly, 
Foslip, unlike Foscan, showed hardly any dark-toxicity at the concentrations used in the present 
study. This later finding was again in good agreement with those of the study with the human 
biliary cancer cell lines
35
 due to the considerable toxicity of ethanol/propandiol (data not shown), 
which is used as a solvent for Foscan in place of water for Foslip.  
Crucial for the success of PDT in cancer therapy is a predominant uptake of PS by tumor 
compared to healthy tissue. This was indeed observed in vivo and ex vivo for i.v. administered 
Foscan and Foslip in both osteosarcoma mouse models investigated in the present study. These 
results confirmed a previously reported higher content of both formulations in tumor than in 
adjacent muscle tissue
27, 36
. Two mechanisms have been proposed to account for these findings. 
Both Foscan and Foslip bind to serum proteins such as albumin and high and low density 
lipoproteins (HDL/LDL) that facilitate their cellular uptake, which is apparently accelerated in fast 
proliferating cancer cells that are dependent on a high transport rate of lipoproteins
37, 38
. Increased 
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PS uptake in tumor compared to healthy tissue is also caused by anatomical changes within the 
tumor, characterized by an enhanced leakiness of tumor blood vessels, and a slower lymphatic 
drainage, causing an accumulation of the PS in the tumor tissue, called the enhanced permeability 
and retention (EPR) effect
39, 40
.  
The results of the here reported experiments, analyzing the time-dependent uptake of 
mTHPC by tumor tissue, showed a significantly higher uptake of Foslip than of Foscan at all time 
points investigated in the 143B/SCID model and at 6 hours after mTHPC administration in the 
K7M2L2/BALB/c model. These observations are consistent with the findings of De Visscher et 
al., who reported a significantly higher increase of Foslip than of Foscan fluorescence intensities 
upon i.v. PS administration in a subcutaneous adenocarcinoma mouse model
41
. Thus, Foslip 
appears to enhance the bioavailability of mTHPC in tumor tissue. Along these lines, it is assumed 
that liposomal carriers enhance the EPR effect due to the formation of larger macromolecules upon 
binding to plasma proteins
42, 43
.  
Already 20 years ago, pioneering studies performed by Korbelik et al., demonstrated the 
importance of an intact immune system for the efficacy of PDT
44
. A comparison of the efficacy of 
PDT in immune-compromised and in immune-competent mice in the present study confirmed the 
important findings of Korbelik et al. PDT with Foscan and Foslip only transiently inhibited the 
growth of intratibial 143B cell line-derived tumors in SCID mice and had no significant effect on 
lung metastasis. In immune-competent BALB/c mice, however, the growth of K7M2L2 cell line-
derived primary tumors was persistently suppressed and the formation of both micro- and macro-
metastases significantly inhibited by PDT with the two PS formulations. Additionally, our findings 
indicate increased infiltration of T-lymphocytes at the primary tumor site, pointing to a PDT 
activated T cell adaptive immunity that decreases pulmonary metastasis. Altogether, the findings 
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confirmed the important impact of an intact immune system on PDT efficacy reported by Korbelik 
et al. and needs to be further explored.  
Due to enhanced angiogenesis in the tumor bearing leg, blood flow was significantly 
enhanced in all groups of mice before photodynamic treatment. Analysis of tumor vascularization 
and perfusion in the K7M2L2/BALB/c model demonstrated a pronounced inhibitory effect of the 
PDT on the blood supply of the primary tumor. These observations are consistent with reported 
toxic and inhibitory effects of PDT on endothelial cells and platelet formation, respectively, 
leading to vascular leakage and collapse and, consequently, an impaired blood flow in the treated 
tumor bearing leg 
11, 45, 46
. However, this effect was only temporary, likely due to compensatory 
mechanisms in non-damaged neighboring blood vessels that restored the blood flow to levels 
before treatment. Since angiogenesis plays a major role in tumor progression, targeting tumor 
vascularization by PDT has an additional at least transient beneficial tumor suppressive effect
47
.  
Interestingly, in the 143B/SCID model, Foslip was more effective than Foscan, presumably 
due to the observed higher amounts of mTHPC accumulating in tumors of Foslip than of Foscan-
treated mice and to previously reported higher concentrations of monomeric mTHPC achieved 
with liposomal formulations, as hydrophobic PS (Foscan) strongly aggregate in aqueous media 
weakening their photosensitizing efficacy
37, 42
.  
Differences in efficacy between Foscan- based and Foslip-based PDT was only observed in 
the xenograft mouse model, further studies are needed to evaluate additional treatment setting for 
both mTHPC formulations. The relation of the liposomal carrier system and their 
pharmacokinetics to PDT efficacy is still under debate. Previous studies in preclinical mammary 
carcinoma and fibrosarcoma models showed no correlation of the PS concentrations in the tumor 
and PDT efficacy, indicating a correlation between PDT efficacy and PS concentration in 
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endothelial cells 
48, 49
. On the other side, d`Hallewin et al. demonstrated the importance of Foslip 
accumulation in the tumor tissue, giving rise to the highest amount of tumor necrosis with the 
highest PS concentration in the tumor
50
. Our results provide a first hint that in osteosarcoma, 
Foslip is equally potent compared to Foscan, but to truly compare the PDT efficiency between 
both compounds, further studies are needed. 
In summary, this study demonstrates potent mTHPC-based PDT-mediated tumor 
suppressive effects in two clinically relevant intratibial mouse models of osteosarcoma, and clearly 
demonstrates the potential of PDT to inhibit lung metastatic growth in animals with an intact 
immune system. Considering that PDT has a relatively low systemic toxicity, repetitive application 
is possible. Consequently, it is an interesting novel option for the treatment of osteosarcoma, even 
in combination with current standards of care including neoadjuvant chemotherapy. 
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Figure Legends 
Figure 1. Dose- and time-dependent uptake of Foscan and Foslip in 143B and K7M2L2 
osteosarcoma cells. Cells were incubated in the dark with either Foscan (■) or Foslip (●) with 
the indicated concentrations of mTHPC for 5 h (a) or with 2.5 µg/ml mTHPC for indicated 
time periods (b). After washing with PBS, mTHPC fluorescence intensity (indicated as relative 
fluorescence unit (RFU)) was measured at 652 nm after excitation at 452 nm. * P < 0.05, ** P 
< 0.01, Foscan compared with Foslip. (c) Representative images of cellular localization of 
mTHPC by confocal laser scanning microscopy in 143B and K7M2L2 cells. mTHPC 
fluorescence appeared red and nuclei stained with Hoechst appeared blue, 20-fold 
magnification, scale bar, 100 µm.  
Figure 2. Dark- and photo-toxicity of Foscan and Foslip in 143B and K7M2L2 osteosarcoma 
cells, and PDT induced apoptosis. (a) Dose-dependent dark-toxicity. 143B (left panel) and 
K7M2L2 (right panel) cells (2000 cells/ well) were incubated in the dark in the absence 
(control, set to 100%) or in the presence of indicated concentrations of mTHPC (Foscan ■, 
Foslip ●) for 5 h. Cell viability was assessed in a WST-1 assay. (b) Dose-dependent photo-
toxicity. 143B (left panel) and K7M2L2 (right panel) cells (800 cells/ well) were incubated in 
the dark in the absence (control, set to 100%) or in the presence of indicated concentrations of 
mTHPC for 5 h and subsequently illuminated with doses of 1 J/cm
2 
(Foscan □, Foslip ○) or 5 
J/cm
2
 (Foscan ■, Foslip ●) of 652 nm laser light. The cell viability was determined as in (a). 
(c) Inhibition of PDT-induced PARP cleavage by Z-VAD-FMK in 143B cells. The cells were 
pre-incubated in the absence or presence of Z-VAD-FMK or DMSO and treated with Foscan 
(left panel) or Foslip (right panel) at indicated concentrations and subjected to PDT as 
Page 27 of 37
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
  
28
described in Materials and Methods. (d) Inhibition of PARP cleavage by Z-VAD-FMK in 
K7M2L2 subjected to PDT as described in (c). GAPDH was used as protein loading controls. 
 Figure 3. Uptake of Foscan or Foslip by intratibial human xenograft 143B cell line-derived 
tumors in SCID mice and by intratibial mouse K7M2L2 cell line-derived tumors in syngeneic 
BALB/c mice. SCID and BALB/c mice with tumors > 50 mm
3
 were i.v. injected with Foscan 
or Foslip equivalent to 1.5 mg/kg mTHPC and the uptake of the mTHPC formulations by 
tumor tissue over time was assessed with a fluorimeter as described in Materials and Methods. 
Fluorescence measurements were corrected for background fluorescence of tumor tissue, 
assessed in non-injected mice (no mTHPC). (a) Mean (± SEM) uptake (indicated as RFU) in 
vivo of listed mTHPC formulations at indicated time points by 143B cell line-derived tumors 
(n=10) and (b) by K7M2L2 cell line-derived tumors (n=14). .* P < 0.05, ** P < 0.01, *** P < 
0.001 Foslip compared to Foscan (2-way ANOVA, Bonferroni post-test). (c) Mean (± SEM) 
uptake (RFU) of indicated formulations assessed ex vivo 48 h after PS injection in 143B cell 
line-derived tumors (n=10) and in corresponding healthy leg tissue (control leg) and (d) in 
K7M2L2 cell line-derived tumors (n=14) and in control legs. * P < 0.05, ** P < 0.01, *** P < 
0.001 tumor leg compared to control leg, n.s.: not significant (1-way ANOVA, Bonferroni 
post-test). (e) Ex vivo visualization of mTHPC (red) in cryosections (fluorescence filter 
~620nm) of primary tumor tissue of Foscan- or Foslip- and non-injected mice. White arrows 
point to muscle fibers surrounded by tumor tissue. Scale bar, 200 µm. 
Figure 4. Inhibition of osteosarcoma primary tumor growth in two intratibial osteosarcoma 
mouse models in response to Foscan or Foslip based PDT (i.v. PS administration equivalent to 
0.15 mg/kg mTHPC, 20 J/cm
2
). (a) Mean (± SEM) fold change in size of intratibial human 
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143B cell line-derived tumors in SCID mice (10 control, 7 Foscan and 7 Foslip-treated mice) 
and (b) of intratibial mouse K7M2L2 cell line-derived tumors in syngeneic BALB/c mice (15 
control, 8 Foscan and 9 Foslip-treated mice) assessed on indicated days after PDT by caliper 
measurements and normalized to the tumor size in individual mice measured on the day of 
PDT treatment. The control groups of mice received PS but no laser light illumination 
(control). (c) Photographs taken on day of PDT and at the end of treatment study from 
representative SCID mice with intratibial 143B cell line-derived tumors and (d) from 
representative BALB/c mice with intratibial K7M2L2 cell line-derived tumors in the right hind 
limb. The mice were treated as indicated. + P < 0.05, +++ P < 0.001 Foscan PDT vs. control, 
*** P < 0.001 Foslip PDT vs. control. Dotted lines indicate tumor areas. (e) Representative 
images of 5 µm sections of K7M2L2 cell line-derived intratibial tumors collected two days 
after PDT from BALB/c mice treated as indicated. The sections were stained with hematoxylin 
and eosin (HE) for histological examination and immunostained for cleaved caspase 3 (CC3) 
indicating apoptotic tissue areas. N: necrosis, V: viable tumor, black arrows indicate apoptotic 
cells. Scale bars: top panel, 1 mm, bottom panel, 100 µm.  
Figure 5. Effect of intratibial primary tumor treatment by PDT on pulmonary metastases and 
immune cell infiltration. (a) Ex vivo quantification of X-Gal stained 143B/LacZ cell-derived 
metastases on the surface of whole mounts of lungs collected from SCID mice at sacrifice 14 
days after PDT. The data indicate the numbers of pulmonary micrometastases per lung 
(diameter < 0.1mm, left panel) and of pulmonary macrometastases (diameter > 0.1mm, right 
panel) in individual mice of the indicated treatment groups. The numbers of lungs analyzed in 
the different experimental groups are shown by the number of corresponding symbols in the 
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figures. (b) Ex vivo quantification of X-Gal stained K7M2L2/LacZ cells on whole mounts of 
lungs collected from BALB/c mice at sacrifice 10 days after treatment. Data analysis as 
described in (a). (c) Representative images of X-gal–stained metastatic nodules on whole 
mounts of lungs of SCID mice and BALB/c mice. Black arrows point to pulmonary 
micrometastases and the open black arrow to a macrometastasis. Scale bar, 200 µm. (d) Mean 
(± SEM) number of T-lymphocytes per high power field (HPF) in primary tumor periphery. (e) 
Mean (± SEM) number of T-lymphocytes per high power field (HPF) in primary tumor core. 
(f) Representative images of H&E stained 5 µm sections of intratibial tumors collected 10 days 
after PDT from BALB/c mice treated as indicated. T-lymphocytes were identified by 
immunohistochemistry for the CD3 antigen (arrows) in the core (red rectangle) and at the 
periphery (green rectangle) of the tumors. V: viable tumor tissue, N: necrotic tumor tissue, pln: 
popliteal lymph node (on slide positive tissue control), *: soft tissue adjacent to the tumor. 
Scale bars: low magnification panel, 5 mm, high magnification panels, 50 µm. * P < 0.05, ** 
P < 0.01, *** P < 0.001, PDT-treated groups vs. control, n.s.: not significant.   
 
Figure 6. Effect of primary tumor treatment by Foscan or Foslip-based PDT on hind limb 
blood flow in the syngeneic K7M2L2/BALB/c osteosarcoma mouse model. (a) Blood flow in 
control and tumor-bearing hind limbs was measured with a laser Doppler perfusion imager in 
the regions of interest (ROI) (as indicated in b), and the data collected from 12 mice per 
treatment group on indicated experimental days are presented as percent change in perfusion 
(flux) of tumor compared to normal tissue, *** P < 0.001 PDT- treated vs. control. (b) Images 
of hind limb perfusion taken on indicated experimental days from representative mice of the 
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different experimental groups. White circles indicate ROI for laser Doppler image analysis. (c) 
Representative images of CD31 immunostained 10 µm sections of intratibial tumors collected 
from representative mice of the indicated treatment groups on day 2 after PDT. Black arrows 
point to CD31-stained endothelial cells, scale bar 250 µm. 
 
Supporting Information Table 1. Half-maximal cell viability inhibitory doses (IC50) of 
Foscan and Foslip in 143B and K7M2L2 osteosarcoma cells subjected to PDT with light 
energy doses of 1J/cm
2
 or 5 J/cm
2
 as indicated. 
Supporting Information Figure 1. 10
6
 143B (a) or K7M2L2 (b) cells were incubated for 5 h 
with Foscan or Foslip at indicated mTHPC concentrations. Osteosarcoma cells were 
illuminated (as described in Material and Methods) or kept in the dark. Cell lysates were 
analyzed with antibodies to cleaved caspase 3 (1:1000, Cell Signaling Technology, Danvers, 
MA), to cleaved caspase 7 (1:1000, Cell Signaling Technology), to caspase 9 and cleaved 
caspase 9 (1:1000, Cell Signaling Technology), to PARP and cleaved PARP (1:1000, Cell 
Signaling Technology), to GAPDH (1:3000 Santa Cruz Biotechnologies) and to Actin 
(1:10`000, Millipore Darmstadt, Germany). GAPDH and Actin were used as protein loading 
controls. 
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Figure 1. Dose- and time-dependent uptake of Foscan and Foslip in 143B and K7M2L2 osteosarcoma cells. 
Cells were incubated in the dark with either Foscan (■) or Foslip (●) with the indicated concentrations of 
mTHPC for 5 h (a) or with 0.6 µg/ml mTHPC for indicated time periods (b). After washing with PBS, mTHPC 
fluorescence intensity (indicated as relative fluorescence unit (RFU)) was measured at 652 nm after 
excitation at 452 nm. * P < 0.05, ** P < 0.01, Foscan compared with Foslip. (c) Representative images of 
cellular localization of mTHPC by confocal laser scanning microscopy in 143B and K7M2L2 cells. mTHPC 
fluorescence appeared red and nuclei stained with Hoechst appeared blue, 20-fold magnification, scale bar, 
100 µm.  
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Figure 2. Dark- and photo-toxicity of Foscan and Foslip in 143B and K7M2L2 osteosarcoma cells, and PDT 
induced apoptosis. (a) Dose-dependent dark-toxicity. 143B (left panel) and K7M2L2 (right panel) cells (2000 
cells/ well) were incubated in the dark in the absence (control, set to 100%) or in the presence of indicated 
concentrations of mTHPC (Foscan ■, Foslip ●) for 5 h. Cell viability was assessed in a WST-1 assay. (b) 
Dose-dependent photo-toxicity. 143B (left panel) and K7M2L2 (right panel) cells (800 cells/ well) were 
incubated in the dark in the absence (control, set to 100%) or in the presence of indicated concentrations of 
mTHPC for 5 h and subsequently illuminated with doses of 1 J/cm2 (Foscan □, Foslip ○) or 5 J/cm2 (Foscan ■, 
Foslip ●) of 652 nm laser light. The cell viability was determined as in (a). (c) Inhibition of PDT-induced 
PARP cleavage by Z-VAD-FMK in 143B cells. The cells were pre-incubated in the absence or presence of Z-
VAD-FMK or DMSO and treated with Foscan (left panel) or Foslip (right panel) at indicated concentrations 
and subjected to PDT as described in Materials and Methods. (d) Inhibition of PARP cleavage by Z-VAD-FMK 
in K7M2L2 subjected to PDT as described in (c). GAPDH was used as protein loading controls.  
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Figure 3. Uptake of Foscan or Foslip by intratibial human xenograft 143B cell line-derived tumors in SCID 
mice and by intratibial mouse K7M2L2 cell line-derived tumors in syngeneic BALB/c mice. SCID and BALB/c 
mice with tumors > 50 mm3 were i.v. injected with Foscan or Foslip equivalent to 1.5 mg/kg mTHPC and the 
uptake of the mTHPC formulations by tumor tissue over time was assessed with a fluorimeter as described 
in Materials and Methods. Fluorescence measurements were corrected for background fluorescence of tumor 
tissue, assessed in non-injected mice (no mTHPC). (a) Mean (± SEM) uptake (indicated as RFU) in vivo of 
listed mTHPC formulations at indicated time points by 143B cell line-derived tumors (n=10) and (b) by 
K7M2L2 cell line-derived tumors (n=14). .* P < 0.05, ** P < 0.01, *** P < 0.001 Foslip compared to 
Foscan (2-way ANOVA, Bonferroni post-test). (c) Mean (± SEM) uptake (RFU) of indicated formulations 
assessed ex vivo 48 h after PS injection in 143B cell line-derived tumors (n=10) and in corresponding 
healthy leg tissue (control leg) and (d) in K7M2L2 cell line-derived tumors (n=14) and in control legs. * P < 
0.05, ** P < 0.01, *** P < 0.001 tumor leg compared to control leg, n.s.: not significant (1-way ANOVA, 
Bonferroni post-test). (e) Ex vivo visualization of mTHPC (red) in cryosections (fluorescence filter ~620nm) 
of indicated primary tumor tissue of Foscan- or Foslip- and non-injected mice. White arrows point to muscle 
fibers surrounded by tumor tissue. Scale bar, 200 µm.  
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Figure 4. Inhibition of osteosarcoma primary tumor growth in two intratibial osteosarcoma mouse models in 
response to Foscan or Foslip based PDT (i.v. PS administration equivalent to 0.15 mg/kg mTHPC, 20 J/cm2). 
(a) Mean (± SEM) fold change in size of intratibial human 143B cell line-derived tumors in SCID mice (10 
control, 7 Foscan and 7 Foslip-treated mice) and (b) of intratibial mouse K7M2L2 cell line-derived tumors in 
syngeneic BALB/c mice (15 control, 8 Foscan and 9 Foslip-treated mice) assessed on indicated days after 
PDT by caliper measurements and normalized to the tumor size in individual mice measured on the day of 
PDT treatment. The control groups of mice received PS but no laser light illumination (control). (c) 
Photographs taken on day of PDT and at the end of treatment study from representative SCID mice with 
intratibial 143B cell line-derived tumors and (d) from representative BALB/c mice with intratibial K7M2L2 cell 
line-derived tumors in the right hind limb. The mice were treated as indicated. + P < 0.05, +++ P < 0.001 
Foscan PDT vs. control, *** P < 0.001 Foslip PDT vs. control. Dotted lines indicate tumor areas. (e) 
Representative images of 5 µm sections of K7M2L2 cell line-derived intratibial tumors collected two days 
after PDT from BALB/c mice treated as indicated. The sections were stained with hematoxylin and eosin (HE) 
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for histological examination and immunostained for cleaved caspase 3 (CC3) indicating apoptotic tissue 
areas. N: necrosis, V: viable tumor, black arrows indicate apoptotic cells. Scale bars: top panel, 1 mm, 
bottom panel, 100 µm.  
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Figure 5. Effect of intratibial primary tumor treatment by PDT on pulmonary metastases and immune cell 
infiltration. (a) Ex vivo quantification of X-Gal stained 143B/LacZ cell-derived metastases on the surface of 
whole mounts of lungs collected from SCID mice at sacrifice 14 days after PDT. The data indicate the 
numbers of pulmonary micrometastases per lung (diameter < 0.1mm, left panel) and of pulmonary 
macrometastases (diameter > 0.1mm, right panel) in individual mice of the indicated treatment groups. The 
numbers of lungs analyzed in the different experimental groups are shown by the number of corresponding 
symbols in the figures. (b) Ex vivo quantification of X-Gal stained K7M2L2/LacZ cells on whole mounts of 
lungs collected from BALB/c mice at sacrifice 10 days after treatment. Data analysis as described in (a). (c) 
Representative images of X-gal–stained metastatic nodules on whole mounts of lungs of SCID mice and 
BALB/c mice. Black arrows point to pulmonary micrometastases and the open black arrow to a 
macrometastasis. Scale bar, 200 µm. (d) Mean (± SEM) number of T-lymphocytes per high power field 
(HPF) in primary tumor periphery. (e) Mean (± SEM) number of T-lymphocytes per high power field (HPF) in 
primary tumor core. (f) Representative images of H&E stained 5 µm sections of intratibial tumors collected 
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10 days after PDT from BALB/c mice treated as indicated. T-lymphocytes were identified by 
immunohistochemistry for the CD3 antigen (arrows) in the core (red rectangle) and at the periphery (green 
rectangle) of the tumors. V: viable tumor tissue, N: necrotic tumor tissue, pln: popliteal lymph node (on 
slide positive tissue control), *: soft tissue adjacent to the tumor. Scale bars: low magnification panel, 5 
mm, high magnification panels, 50 µm. * P < 0.05, ** P < 0.01, *** P < 0.001, PDT-treated groups vs. 
control, n.s.: not significant.    
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Figure 6. Effect of primary tumor treatment by Foscan or Foslip-based PDT on hind limb blood flow in the 
syngeneic K7M2L2/BALB/c osteosarcoma mouse model. (a) Blood flow in control and tumor-bearing hind 
limbs was measured with a laser Doppler perfusion imager in the regions of interest (ROI) (as indicated in 
b), and the data collected from 12 mice per treatment group on indicated experimental days are presented 
as percent change in perfusion (flux) of tumor compared to normal tissue, *** P < 0.001 PDT- treated vs. 
control. (b) Images of hind limb perfusion taken on indicated experimental days from representative mice of 
the different experimental groups. White circles indicate ROI for laser Doppler image analysis. (c) 
Representative images of CD31 immunostained 10 µm sections of intratibial tumors collected from 
representative mice of the indicated treatment groups on day 2 after PDT. Black arrows point to CD31-
stained endothelial cells, scale bar 250 µm.  
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